Ambagon therapeutics One of its most innovative trailblazers, Ambagon Therapeutics, launched at MBC BioLabs in 2020. Ambagon focuses on disordered proteins, which occupy one of the most difficult to reach and potentially fertile regions of undruggability. These proteins offer limited structure for a drug to bind or contain significant regions lacking organization.Mar 1, 2023 · Ambagon Therapeutics This Dutch-American company is developing‘molecular glue’ therapies. The therapies target previously undrugged or difficult to drug disordered proteins, – with an initial focus on oncology and opportunity to expand to other diseases. Mark: “First, I would actually like to know: what is a molecular glue?” Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins. Ambagon’s platform... obvious ventures Ambagon Therapeutics. Contact. Connect with experts in your field. Join ResearchGate to contact this researcher and connect with your scientific community. Join for free. Log in. Contact. Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discovery Jan 11, 2026 · The biotechnology start-up Ambagon Therapeutics has raised 75 million euros (85 million dollars) in a financing round. With the money, the Dutch-American company will develop medicines that can be used to better treat cancer in the future. Steve is Board Director at Kyverna Therapeutics, Totus Medicines, Opna Bio, and Parthenon Therapeutics, and is a Board Observer at 1859 Inc., Artisan Bio, Ori Biotech, Kytopen, and Stride Bio. Previously, Steve was Director of Portfolio Decision Resources at Sanofi, where he led global strategy and resource prioritization for Sanofi Oncology. Jan 11, 2026 · The biotechnology start-up Ambagon Therapeutics has raised 75 million euros (85 million dollars) in a financing round. With the money, the Dutch-American company will develop medicines that can be used to better treat cancer in the future. Ambagon Therapeutics, a San Francisco CA-based biotechnology company, raised $85M in Series A funding. The round was led by Nextech Invest with participation … quantum si Jan 6, 2026 · Biotech startup Ambagon Therapeutics is taking a new approach to making elusive protein targets “druggable” by using molecular glues. The biotech has a pipeline of preclinical cancer drugs and it... Private Company "Ambagon Therapeutics develops first-in-class small-molecule therapeutics for cancer by augmenting the tumor-suppressing functions of the 14-3-3 protein, a truly novel approach for inhibiting oncogenic transcription factors for cancers with defined drivers, such as breast cancer.Apr 26, 2022 · Ambagon Therapeutics is a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules. Ambagon applies deep knowledge of 14-3-3 proteins and a proprietary suite of drug discovery tools to create molecular glues that stabilize 14-3-3:target complexes. Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discovery Sep 12, 2026 · Ambagon Therapeutics (Eindhoven, NL and San Francisco US) is developing first-in-class cancer drugs through targeted stabilization of 14-3-3 protein complexes – ambagontx.com Arcus Biosciences (Hayward, California; NYSE:RCUS) develops small-molecules and antibodies to compose proprietary immune-oncology combinations. Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discovery Host: Michelle Arkin REGISTRATION FORMAmbagon Therapeutics, a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules, raised USD 85 million in a Series A funding round led by Nextech Invest on 6 January 2022.Building on unique founders’ expertise in the biology of 14-3-3 proteins, Ambagon is developing first in class stabilizers of protein-protein interactions as novel targeted cancer treatments. View this Case Smarter medical research with Castor Castor is a medical software development company based in Amsterdam. rp home and harvest Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discoveryBuilding on unique founders’ expertise in the biology of 14-3-3 proteins, Ambagon is developing first in class stabilizers of protein-protein interactions as novel targeted cancer treatments. View this Case Smarter medical research with Castor Castor is a medical software development company based in Amsterdam. Ambagon Therapeutics | 2.727 volgers op LinkedIn. Expanding the druggable proteome to drug intrinsically disordered proteins. | Ambagon is discovering and developing small …Ambagon Therapeutics Molecular glues are alive and well in San Francisco too, and are being developed by Ambagon Therapeutics. The company celebrated the new year with an $85 million Series A led by Swiss VC firm Nextech Invest.Ambagon Therapeutics, a San Francisco CA-based biotechnology company, raised $85M in Series A funding. The round was led by Nextech Invest with participation …Jan 6, 2022 · SAN FRANCISCO, Calif., January 06, 2026 – Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The financing was led by Nextech Invest. Ambagon Therapeutics This Dutch-American company is developing‘molecular glue’ therapies. The therapies target previously undrugged or difficult to drug disordered proteins, – with an initial focus on oncology and opportunity to expand to other diseases. Mark: “First, I would actually like to know: what is a molecular glue?” southwest marine and general insurance company AmbAgon Therapeutics Inc. (Filer) CIK: 0001819934 (see all company filings) IRS No.: 850560627 | State of Incorp.: DE | Fiscal Year End: 1231 Type: D | Act: 33 | File No.: 021-429995 | Film No.: 22539432 Ambagon Therapeutics aims to develop first in class protein-protein interaction stabilizer drugs as novel targeted cancer treatments. Ambagon says its approach opens up novel target space as well as having an innovative mechanism of action. Protein–protein interactions (PPIs) are one of the core processes by which cells function …Apr 26, 2022 · Ambagon Therapeutics is a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules. Ambagon applies deep knowledge of 14-3-3 proteins... Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The financing was led by Nextech Invest.Jan 4, 2023 · Top Life Sciences Startups to Watch in 2023 Read More BioCentury | February 1, 2026 Ambagon: creating molecular glues for disordered proteins Read More Publications & Presentations Molecular glues to stabilise protein-protein interactions Current Opinion in Chemical Biology. 2022. Information on valuation, funding, cap tables, investors, and executives for Ambagon Therapeutics. Use the PitchBook Platform to explore the full profile.Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discovery Host: Michelle Arkin REGISTRATION FORM bearing technologies Biotech startup Ambagon Therapeutics is taking a new approach to making elusive protein targets “druggable” by using molecular glues. The biotech has a pipeline of preclinical cancer drugs and it...Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The financing was led by Nextech Invest.Apr 26, 2022 · Ambagon Therapeutics is a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules. Ambagon applies deep knowledge of 14-3-3 proteins and a proprietary suite of drug discovery tools to create molecular glues that stabilize 14-3-3:target complexes. Jan 4, 2026 · 1. Neumora Therapeutics, Inc. Launched: October 2021 Location: Watertown, MA Series A: $400M Notable: It’s no surprise that the highest Series A investment of the class went to a biotech developing precision medicines in the sizzling neuro space. A year later, Neumora netted another $112 million in Series B funding . SAN FRANCISCO-- ( BUSINESS WIRE )-- Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered protein targets with novel molecular glues, today announced the appointment of ...Sep 12, 2022 · We are specialists, investing exclusively in therapeutics for oncology and genetic disease. Our focus and our in-house team of drug development experts and biotech professionals allow us to accelerate our companies’ progress by actively supporting them from company creation through clinical proof of concept. safelite fulfillment inc Jan 11, 2026 · The biotechnology start-up Ambagon Therapeutics has raised 75 million euros (85 million dollars) in a financing round. With the money, the Dutch-American company will develop medicines that can be used to better treat cancer in the future. Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discovery Host: Michelle Arkin REGISTRATION FORM Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discovery Ambagon’s approach selectively augments the endogenous tumor suppression activity of 14-3-3 proteins bound to transcription factors and oncoproteins that have proven challenging to modulate with conventional approaches.4mo Report this post Report Report BackSubmit We’re delighted to welcome Donna Olivia Debets, Ph.D., Scientist, Proteomics, to our Eindhoven team! We look forward to the impact Donna’s... Steve is Board Director at Kyverna Therapeutics, Totus Medicines, Opna Bio, and Parthenon Therapeutics, and is a Board Observer at 1859 Inc., Artisan Bio, Ori Biotech, Kytopen, and Stride Bio. Previously, Steve was Director of Portfolio Decision Resources at Sanofi, where he led global strategy and resource prioritization for Sanofi Oncology. The biotechnology start-up Ambagon Therapeutics has raised 75 million euros (85 million dollars) in a financing round. With the money, the Dutch-American company will develop medicines that can be used to better treat cancer in the future. Ambagon was founded in 2020 on the basis of a number of years of research at TU …Steve is Board Director at Kyverna Therapeutics, Totus Medicines, Opna Bio, and Parthenon Therapeutics, and is a Board Observer at 1859 Inc., Artisan Bio, Ori Biotech, Kytopen, and Stride Bio. Previously, Steve was Director of Portfolio Decision Resources at Sanofi, where he led global strategy and resource prioritization for Sanofi Oncology.Jun 23, 2022 · 7 Citations 4 Altmetric Metrics Abstract Impaired activity of the chloride channel CFTR is the cause of cystic fibrosis. 14-3-3 proteins have been shown to stabilize CFTR and increase its... bolt venturestrue influence Private Company "Ambagon Therapeutics develops first-in-class small-molecule therapeutics for cancer by augmenting the tumor-suppressing functions of the 14-3-3 protein, a truly novel approach for inhibiting oncogenic transcription factors for cancers with defined drivers, such as breast cancer. Private Company "Ambagon Therapeutics develops first-in-class small-molecule therapeutics for cancer by augmenting the tumor-suppressing functions of the 14-3-3 protein, a truly novel approach for inhibiting oncogenic transcription factors for cancers with defined drivers, such as breast cancer. kenneth kennyBuilding on unique founders’ expertise in the biology of 14-3-3 proteins, Ambagon is developing first in class stabilizers of protein-protein interactions as novel targeted cancer treatments. View this Case Smarter medical research with Castor Castor is a medical software development company based in Amsterdam. The biotechnology start-up Ambagon Therapeutics has raised 75 million euros (85 million dollars) in a financing round. With the money, the Dutch-American company will develop medicines that can be used to better treat cancer in the future. Ambagon was founded in 2020 on the basis of a number of years of research at TU …953 Indiana Street San Francisco, CA 94107 United States +1 (650) 000-0000 Ambagon Therapeutics Timeline 2020 2021 2022 2023 Financing Round Captured Employee Count Estimated Employee Growth Want detailed data on 3M+ companies?Ambagon Therapeutics aims to develop first in class protein-protein interaction stabilizer drugs as novel targeted cancer treatments. Ambagon says its approach opens up novel target space as well as having an innovative mechanism of action. Protein–protein interactions (PPIs) are one of the core processes by which cells function …Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discovery general trailer parts llc Ambagon Therapeutics By taming disordered proteins, Ambagon generates new possibilities across the proteome. READ ON Cartography Biosciences Cartography emerged from stealth in July 2022 with $57 million in initial financing to create more precise immunotherapies.Find company research, competitor information, contact details & financial data for Ambagon Therapeutics Inc. of San Francisco, CA. Get the latest business insights from …Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discovery Host: Michelle Arkin REGISTRATION FORMFunding. AmbAgon Therapeutics has raised a total of $148M in funding over 3 rounds. Their latest funding was raised on May 27, 2026 from a Venture - Series Unknown round. AmbAgon Therapeutics is funded by 8 investors. Mission BioCapital and RA Capital Management are the most recent investors.Biotech company Ambagon Therapeutics, a spin-off from Eindhoven University of Technology (TU/e) in the Netherlands, is developing new treatment therapies based on proteins that are instrumental in treating cancer and other diseases. In this instalment of start-up of the day, founders Luc Brunsveld and Christian Ottmann talk …Sep 12, 2022 · Ambagon Therapeutics (Eindhoven, NL and San Francisco US) is developing first-in-class cancer drugs through targeted stabilization of 14-3-3 protein complexes – ambagontx.com Arcus Biosciences (Hayward, California; NYSE:RCUS) develops small-molecules and antibodies to compose proprietary immune-oncology combinations. Ambagon Therapeutics USA Private Ambagon applies deep knowledge of 14-3-3 proteins and a proprietary suite of drug discovery tools to create molecular glues that stabilize 14-3-3:target complexes. These molecular glue stabilizers amplify native biology to restore or inhibit target function, potentiate target activity, or promote or block target ...Apr 26, 2022 · Ambagon Therapeutics is a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules. Ambagon applies deep knowledge of 14-3-3 proteins and a proprietary suite of drug discovery tools to create molecular glues that stabilize 14-3-3:target complexes. Ambagon Therapeutics This Dutch-American company is developing‘molecular glue’ therapies. The therapies target previously undrugged or difficult to drug disordered proteins, – with an initial focus on oncology and opportunity to expand to other diseases. Mark: “First, I would actually like to know: what is a molecular glue?” varsity produceSAN FRANCISCO-- ( BUSINESS WIRE )-- Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85...953 Indiana Street San Francisco, CA 94107 United States +1 (650) 000-0000 Ambagon Therapeutics Timeline 2020 2021 2022 2023 Financing Round Captured Employee Count Estimated Employee Growth Want detailed data on 3M+ companies?Jan 4, 2023 · Top Life Sciences Startups to Watch in 2023 Read More BioCentury | February 1, 2026 Ambagon: creating molecular glues for disordered proteins Read More Publications & Presentations Molecular glues to stabilise protein-protein interactions Current Opinion in Chemical Biology. 2022. peaksware Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discoveryLuc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discovery Host: Michelle Arkin REGISTRATION FORMLuc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discoveryJan 6, 2022 · SAN FRANCISCO-- ( BUSINESS WIRE )-- Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85... Associate Director Ambagon Therapeutics May 2022 - Present1 year 2 months San Francisco, California, United States Principal Scientist IDEAYA Biosciences Dec 2020 - May 20221 year 6 months San...Oct 7, 2022 · Biotech company Ambagon Therapeutics, a spin-off from Eindhoven University of Technology (TU/e) in the Netherlands, is developing new treatment therapies based on proteins that are instrumental in treating cancer and other diseases. 953 Indiana Street San Francisco, CA 94107 United States +1 (650) 000-0000 Ambagon Therapeutics Timeline 2020 2021 2022 2023 Financing Round Captured Employee Count Estimated Employee Growth Want detailed data on 3M+ companies?AmbAgon Therapeutics is a developer of cancer molecule therapeutics. San Francisco, California, United States 1-10 Venture - Series Unknown Private ambagontx.com/ 18,647 Highlights Total Funding Amount $148M Contacts 14 Employee Profiles 7 Investors 8 Similar Companies 10 Funding Round May 27, 2026 Jan 6, 2026 · SAN FRANCISCO-- ( BUSINESS WIRE )-- Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85... Ambagon Therapeutics, a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules, raised USD 85 million in a Series A funding round led by Nextech Invest on 6 January 2022.Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discovery Host: Michelle Arkin REGISTRATION FORM Jan 6, 2026 · SAN FRANCISCO-- ( BUSINESS WIRE )-- Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The financing was led by Nextech Invest. "Ambagon Therapeutics develops first-in-class small-molecule therapeutics for cancer by augmenting the tumor-suppressing functions of the 14-3-3 protein, a truly novel approach for inhibiting oncogenic transcription factors for cancers with …Jun 28, 2019 · 953 Indiana Street San Francisco, CA 94107 United States +1 (650) 000-0000 Ambagon Therapeutics Timeline 2020 2021 2022 2023 Financing Round Captured Employee Count Estimated Employee Growth Want detailed data on 3M+ companies? Steve is Board Director at Kyverna Therapeutics, Totus Medicines, Opna Bio, and Parthenon Therapeutics, and is a Board Observer at 1859 Inc., Artisan Bio, Ori Biotech, Kytopen, and Stride Bio. Previously, Steve was … skysafe Oct 7, 2026 · Biotech company Ambagon Therapeutics, a spin-off from Eindhoven University of Technology (TU/e) in the Netherlands, is developing new treatment therapies based on proteins that are instrumental in treating cancer and other diseases. Ambagon Therapeutics Dec 2020 - Present2 years 2 months San Francisco, California, United States https://www.ambagon …Find company research, competitor information, contact details & financial data for Ambagon Therapeutics Inc. of San Francisco, CA. Get the latest business insights from … cohn and gregorycrespacelectric eraSep 12, 2026 · Ambagon Therapeutics (Eindhoven, NL and San Francisco US) is developing first-in-class cancer drugs through targeted stabilization of 14-3-3 protein complexes – ambagontx.com Arcus Biosciences (Hayward, California; NYSE:RCUS) develops small-molecules and antibodies to compose proprietary immune-oncology combinations. Ambagon Therapeutics, a San Francisco CA-based biotechnology company, raised $85M in Series A funding. The round was led by Nextech Invest with participation …The biotechnology start-up Ambagon Therapeutics has raised 75 million euros (85 million dollars) in a financing round. With the money, the Dutch-American company will develop medicines that can be used to better treat cancer in the future. Ambagon was founded in 2020 on the basis of a number of years of research at TU …Ambagon Therapeutics. Contact. Connect with experts in your field. Join ResearchGate to contact this researcher and connect with your scientific community. Join for free. Log in. Contact. 360 independence ave mechanicsburg pa 17055 Ambagon Therapeutics By taming disordered proteins, Ambagon generates new possibilities across the proteome. READ ON Cartography Biosciences Cartography emerged from stealth in July 2022 with $57 million in initial financing to create more precise immunotherapies. Dec 5, 2025 · AmbAgon Therapeutics develops first-in-class small-molecule therapeutics for cancer by augmenting the tumor-suppressing functions of the 14-3-3 protein, a truly novel approach for inhibiting... Jan 6, 2026 · Ambagon truly has the potential to change the narrative for disordered targets.” About Ambagon Therapeutics Ambagon Therapeutics is a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules. Ambagon applies deep knowledge of 14-3-3 proteins and a proprietary suite of drug discovery ... Building on unique founders’ expertise in the biology of 14-3-3 proteins, Ambagon is developing first in class stabilizers of protein-protein interactions as novel targeted cancer treatments. View this Case Smarter medical research with Castor Castor is a medical software development company based in Amsterdam.Associate Director Ambagon Therapeutics May 2022 - Present1 year 2 months San Francisco, California, United States Principal Scientist IDEAYA Biosciences Dec 2020 - May 20221 year 6 months San... mni targeted media Jan 6, 2026 · Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The financing was led by Nextech Invest. AmbAgon Therapeutics First-in-class breast cancer drugs through targeted stabilization of protein complexes AmbAgon develops first-in-class small-molecule therapeutics for breast cancer by augmenting the tumor-suppressing functions of the 14-3-3 protein. Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discovery siemens energy houston Sep 12, 2026 · Ambagon Therapeutics (Eindhoven, NL and San Francisco US) is developing first-in-class cancer drugs through targeted stabilization of 14-3-3 protein complexes – ambagontx.com Arcus Biosciences (Hayward, California; NYSE:RCUS) develops small-molecules and antibodies to compose proprietary immune-oncology combinations. Ambagon Therapeutics By taming disordered proteins, Ambagon generates new possibilities across the proteome. READ ON Cartography Biosciences Cartography emerged from stealth in July 2022 with $57 million in initial financing to create more precise immunotherapies. Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discovery Host: Michelle Arkin REGISTRATION FORM lo toneyall4 llcAmbagon Therapeutics (Eindhoven, NL and San Francisco US) is developing first-in-class cancer drugs through targeted stabilization of 14-3-3 protein complexes – ambagontx.com Arcus Biosciences (Hayward, California; NYSE:RCUS) develops small-molecules and antibodies to compose proprietary immune-oncology combinations.One of its most innovative trailblazers, Ambagon Therapeutics, launched at MBC BioLabs in 2020. Ambagon focuses on disordered proteins, which occupy one of the most difficult to reach and potentially fertile regions of … anumex SAN FRANCISCO-- ( BUSINESS WIRE )-- Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85...Oct 7, 2022 · Biotech company Ambagon Therapeutics, a spin-off from Eindhoven University of Technology (TU/e) in the Netherlands, is developing new treatment therapies based on proteins that are instrumental in treating cancer and other diseases. Dec 5, 2025 · AmbAgon Therapeutics develops first-in-class small-molecule therapeutics for cancer by augmenting the tumor-suppressing functions of the 14-3-3 protein, a truly novel approach for inhibiting... 4mo Report this post Report Report BackSubmit We’re delighted to welcome Donna Olivia Debets, Ph.D., Scientist, Proteomics, to our Eindhoven team! We look forward to the impact Donna’s... Published: Jan 06, 2026 By Alvin Clavines. Ambagon Therapeutics, a developer of cancer molecule therapeutics, announced today the closing of its first … evolution powersports watertown south dakota Biotech company Ambagon Therapeutics, a spin-off from Eindhoven University of Technology (TU/e) in the Netherlands, is developing new treatment therapies based on proteins that are instrumental in treating cancer and other diseases. In this instalment of start-up of the day, founders Luc Brunsveld and Christian Ottmann talk …Biotech startup Ambagon Therapeutics is applying its molecular glues to some of the most difficult-to-target proteins, and the preclinical biotech has raised $85 million to advance research that...Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discoveryTop Life Sciences Startups to Watch in 2023 Read More BioCentury | February 1, 2026 Ambagon: creating molecular glues for disordered proteins Read More Publications & Presentations Molecular glues to stabilise protein-protein interactions Current Opinion in Chemical Biology. 2022.Jan 8, 2022 · Ambagon Therapeutics, a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules, raised USD 85 million in a Series A funding round led by Nextech Invest on 6 January 2022. woodward ft collins Jan 4, 2026 · Top Life Sciences Startups to Watch in 2023 Read More BioCentury | February 1, 2026 Ambagon: creating molecular glues for disordered proteins Read More Publications & Presentations Molecular glues to stabilise protein-protein interactions Current Opinion in Chemical Biology. 2022. Biotech startup Ambagon Therapeutics is taking a new approach to making elusive protein targets “druggable” by using molecular glues. The biotech has a pipeline of preclinical cancer drugs and it...Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins. Ambagon’s platform... american express travel related services View Ambagon Therapeutics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.Ambagon Therapeutics By taming disordered proteins, Ambagon generates new possibilities across the proteome. READ ON Cartography Biosciences Cartography emerged from stealth in July 2022 with $57 million in initial financing to create more precise immunotherapies. Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discovery Host: Michelle Arkin REGISTRATION FORMAmbagon Therapeutics By taming disordered proteins, Ambagon generates new possibilities across the proteome. READ ON Cartography Biosciences Cartography emerged from stealth in July 2022 with $57 million in initial financing to create more precise immunotherapies.SAN FRANCISCO-- ( BUSINESS WIRE )-- Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered protein targets with novel molecular glues, today announced the appointment of ... retale We are specialists, investing exclusively in therapeutics for oncology and genetic disease. Our focus and our in-house team of drug development experts and biotech professionals allow us to accelerate our companies’ progress by actively supporting them from company creation through clinical proof of concept.Steve is Board Director at Kyverna Therapeutics, Totus Medicines, Opna Bio, and Parthenon Therapeutics, and is a Board Observer at 1859 Inc., Artisan Bio, Ori Biotech, Kytopen, and Stride Bio. Previously, Steve was Director of Portfolio Decision Resources at Sanofi, where he led global strategy and resource prioritization for Sanofi Oncology. Information on valuation, funding, cap tables, investors, and executives for Ambagon Therapeutics. Use the PitchBook Platform to explore the full profile.One of its most innovative trailblazers, Ambagon Therapeutics, launched at MBC BioLabs in 2020. Ambagon focuses on disordered proteins, which occupy one of the most difficult to reach and potentially fertile regions of …Apr 26, 2022 · Ambagon Therapeutics is a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules. Ambagon applies deep knowledge of 14-3-3 proteins and a proprietary suite of drug discovery tools to create molecular glues that stabilize 14-3-3:target complexes. phi service company Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discovery Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discovery Host: Michelle Arkin REGISTRATION FORM Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discovery Host: Michelle Arkin REGISTRATION FORM workletethe valens companySteve is Board Director at Kyverna Therapeutics, Totus Medicines, Opna Bio, and Parthenon Therapeutics, and is a Board Observer at 1859 Inc., Artisan Bio, Ori Biotech, Kytopen, and Stride Bio. Previously, Steve was Director of Portfolio Decision Resources at Sanofi, where he led global strategy and resource prioritization for Sanofi Oncology. Mar 1, 2026 · Ambagon Therapeutics This Dutch-American company is developing‘molecular glue’ therapies. The therapies target previously undrugged or difficult to drug disordered proteins, – with an initial focus on oncology and opportunity to expand to other diseases. Mark: “First, I would actually like to know: what is a molecular glue?” ecit Ambagon Therapeutics (Eindhoven, NL and San Francisco US) is developing first-in-class cancer drugs through targeted stabilization of 14-3-3 protein complexes – ambagontx.com Arcus Biosciences (Hayward, California; NYSE:RCUS) develops small-molecules and antibodies to compose proprietary immune-oncology combinations.Small molecule stabilizers of protein–protein interactions hold great therapeutic potential. Based on virtual screening and molecular docking, the authors here develop a strategy to evolve weak ... better.com newsLuc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discoveryBiotech company Ambagon Therapeutics, a spin-off from Eindhoven University of Technology (TU/e) in the Netherlands, is developing new treatment therapies based on proteins that are instrumental in treating cancer and other diseases. In this instalment of start-up of the day, founders Luc Brunsveld and Christian Ottmann talk …Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins. Ambagon’s platform...Ambagon Therapeutics is a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules. Ambagon applies deep knowledge of 14-3-3 proteins and a proprietary suite of drug discovery tools to create molecular glues that stabilize 14-3-3:target complexes.Jan 4, 2023 · 1. Neumora Therapeutics, Inc. Launched: October 2021 Location: Watertown, MA Series A: $400M Notable: It’s no surprise that the highest Series A investment of the class went to a biotech developing precision medicines in the sizzling neuro space. A year later, Neumora netted another $112 million in Series B funding . worley houston Ambagon Therapeutics By taming disordered proteins, Ambagon generates new possibilities across the proteome. READ ON Cartography Biosciences Cartography emerged from stealth in July 2022 with $57 million in initial financing to create more precise immunotherapies. SAN FRANCISCO-- ( BUSINESS WIRE )-- Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered protein targets with novel …One of its most innovative trailblazers, Ambagon Therapeutics, launched at MBC BioLabs in 2020. Ambagon focuses on disordered proteins, which occupy one of the most difficult to reach and potentially fertile regions of undruggability. These proteins offer limited structure for a drug to bind or contain significant regions lacking organization. SAN FRANCISCO, Calif., January 06, 2026 – Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to …Steve is Board Director at Kyverna Therapeutics, Totus Medicines, Opna Bio, and Parthenon Therapeutics, and is a Board Observer at 1859 Inc., Artisan Bio, Ori Biotech, Kytopen, and Stride Bio. Previously, Steve was Director of Portfolio Decision Resources at Sanofi, where he led global strategy and resource prioritization for Sanofi Oncology. allied crawford west memphis Ambagon Therapeutics Dec 2020 - Present2 years 2 months San Francisco, California, United States https://www.ambagon …953 Indiana Street San Francisco, CA 94107 United States +1 (650) 000-0000 Ambagon Therapeutics Timeline 2020 2021 2022 2023 Financing Round Captured Employee Count Estimated Employee Growth Want detailed data on 3M+ companies?Biotech startup Ambagon Therapeutics is taking a new approach to making elusive protein targets “druggable” by using molecular glues. The biotech has a pipeline of preclinical cancer drugs and it...Ambagon Therapeutics, a San Francisco CA-based biotechnology company, raised $85M in Series A funding. The round was led by Nextech Invest with participation … acra building supply Ambagon Therapeutics is a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules. Ambagon applies deep knowledge of 14-3-3 proteins and a proprietary suite of drug discovery tools to create molecular glues that stabilize 14-3-3:target complexes.Top Life Sciences Startups to Watch in 2023 Read More BioCentury | February 1, 2026 Ambagon: creating molecular glues for disordered proteins Read More Publications & Presentations Molecular glues to stabilise protein-protein interactions Current Opinion in Chemical Biology. 2022. caban system We are specialists, investing exclusively in therapeutics for oncology and genetic disease. Our focus and our in-house team of drug development experts and biotech professionals allow us to accelerate our companies’ progress by actively supporting them from company creation through clinical proof of concept.Apr 26, 2022 · Ambagon Therapeutics is a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules. Ambagon applies deep knowledge of 14-3-3 proteins... Associate Director Ambagon Therapeutics May 2022 - Present1 year 2 months San Francisco, California, United States Principal Scientist IDEAYA Biosciences Dec 2020 - May 20221 year 6 months San... Ambagon Therapeutics By taming disordered proteins, Ambagon generates new possibilities across the proteome. READ ON Cartography Biosciences Cartography emerged from stealth in July 2022 with $57 million in initial financing to create more precise immunotherapies.Jan 6, 2022 · Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The financing was led by Nextech Invest. colonial pipeline alpharetta SAN FRANCISCO-- ( BUSINESS WIRE )-- Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The financing was led by Nextech Invest.4mo Report this post Report Report BackSubmit We’re delighted to welcome Donna Olivia Debets, Ph.D., Scientist, Proteomics, to our Eindhoven team! We look forward to the impact Donna’s... Find company research, competitor information, contact details & financial data for Ambagon Therapeutics Inc. of San Francisco, CA. Get the latest business insights from … steve cook's bowling supplyOct 7, 2026 · Biotech company Ambagon Therapeutics, a spin-off from Eindhoven University of Technology (TU/e) in the Netherlands, is developing new treatment therapies based on proteins that are instrumental in treating cancer and other diseases. Ambagon Therapeutics is a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules.Steve is Board Director at Kyverna Therapeutics, Totus Medicines, Opna Bio, and Parthenon Therapeutics, and is a Board Observer at 1859 Inc., Artisan Bio, Ori Biotech, Kytopen, and Stride Bio. Previously, Steve was Director of Portfolio Decision Resources at Sanofi, where he led global strategy and resource prioritization for Sanofi Oncology.Ambagon Therapeutics is a biotechnology company that is developing cancer molecule therapeutics. The company has offices in San Carlos, California, and Eindhoven, the Netherlands. On Thursday, it announced that it has raised $85M (approx €75.1M) in its Series A round of funding. The round was led by Nextech Invest. buyerquestnational specialty aggregatesSteve is Board Director at Kyverna Therapeutics, Totus Medicines, Opna Bio, and Parthenon Therapeutics, and is a Board Observer at 1859 Inc., Artisan Bio, Ori Biotech, Kytopen, and Stride Bio. Previously, Steve was Director of Portfolio Decision Resources at Sanofi, where he led global strategy and resource prioritization for Sanofi Oncology.We are specialists, investing exclusively in therapeutics for oncology and genetic disease. Our focus and our in-house team of drug development experts and biotech professionals allow us to accelerate our companies’ progress by actively supporting them from company creation through clinical proof of concept.Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins. Ambagon’s platform..."Ambagon Therapeutics develops first-in-class small-molecule therapeutics for cancer by augmenting the tumor-suppressing functions of the 14-3-3 protein, a truly novel approach for inhibiting oncogenic transcription factors for cancers with …Private Company "Ambagon Therapeutics develops first-in-class small-molecule therapeutics for cancer by augmenting the tumor-suppressing functions of the 14-3-3 protein, a truly novel approach for inhibiting oncogenic transcription factors for cancers with defined drivers, such as breast cancer. multi service technology solutions Ambagon Therapeutics is a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules.Cancer biologist San Mateo, California, United States 471 followers 458 connections Join to view profile Ambagon Therapeutics University of Illinois at Chicago Activity I am so excited to...AmbAgon Therapeutics develops first-in-class small-molecule therapeutics for cancer by augmenting the tumor-suppressing functions of the 14-3-3 protein, a truly novel approach for inhibiting...Luc is co-founder of the 14-3-3 PPI drug discovery company Ambagon Therapeutics and elected member of the KNAW (Royal Dutch Academy of Sciences). Talk Title: Stabilization of Protein-Protein Interactions; from the fundaments of supramolecular chemistry to new opportunities in drug discovery Host: Michelle Arkin REGISTRATION FORM SAN FRANCISCO-- ( BUSINESS WIRE )-- Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to …Ambagon Therapeutics By taming disordered proteins, Ambagon generates new possibilities across the proteome. READ ON Cartography Biosciences Cartography emerged from stealth in July 2022 with $57 million in initial financing to create more precise immunotherapies.7 Citations 4 Altmetric Metrics Abstract Impaired activity of the chloride channel CFTR is the cause of cystic fibrosis. 14-3-3 proteins have been shown to stabilize CFTR and increase its...Private Company "Ambagon Therapeutics develops first-in-class small-molecule therapeutics for cancer by augmenting the tumor-suppressing functions of the 14-3-3 protein, a truly novel approach for inhibiting oncogenic transcription factors for cancers with defined drivers, such as breast cancer.